title: [Pharmacological treatment of mental retardation].
abstract: BACKGROUND
  Mental retardation (MR) is defined by the simultaneous appearance of a low intellectual level and an inability to adapt to the demands of the surroundings, beginning either in childhood or during adolescence. Although it is to expected that in the future it will become possible to treat intellectual disability itself by pharmacological means, at present we can only act on the behavioural and neurological syndromes that accompany MR.
  
  
  CONCLUSIONS
  This review looks at the different pharmacological agents that may improve the problems that usually make it more difficult for a patient with MR to adapt within the family, at school and in the workplace. The neuropsychiatric disorders that most often require pharmacological treatment include attention deficit, hyperactivity, behavioural disorders, autism, anxiety, aggressiveness, self-injury and affective disorders. The most frequently used drugs are stimulants, atypical antipsychotics and selective serotonin reuptake inhibitors (SSRI). Their characteristics and application in the different situations that require medical attention are described. The pharmacological treatment of certain common genetic syndromes that involve MR and which are highly specific in their behavioural expression are also discussed.
authors.affiliation: Hospital de Sabadell, Corporacio Sanitaria Parc Tauli, 08208 Sabadell, España. 7280jap@comb.es
authors.forename: J
authors.initials: J
authors.lastname: Artigas-Pallarés
mesh_terms: D002648:Child; D006801:Humans; D008607:Intellectual Disability / Q000188:drug therapy* / Q000209:etiology / Q000235:genetics; D038901:X-Linked Intellectual Disability / Q000188:drug therapy